Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET

Company Participants

Nareg Sagherian - Executive Director, Global IR

Jerome Durso - President, CEO & Director

Linda Richardson - EVP & Chief Commercial Officer

Michelle Berrey - President, Research & Development and Chief Medical Officer

Andrew Saik - CFO

Conference Call Participants

Yasmeen Rahimi - Piper Sandler & Co.

Ritu Baral - Cowen

Steven Seedhouse - Raymond James & Associates

Michael Yee - Jefferies

Antonio Arce - H.C. Wainwright & Co.

Mayank Mamtani - B. Riley Securities

Thomas Smith - SVB Securities

Eliana Merle - UBS

Luke Herrmann - Robert W. Baird & Co.

Catherine Okoukoni - JMP Securities

Operator

Good day, and thank you for standing by. Welcome to the Q3 2022 Intercept Pharmaceuticals Earnings Call. [Operator Instructions].

I would now like to hand the conference over to your speaker today, Nareg Sagherian, Executive Director, Investor Relations. Please go ahead.

Nareg Sagherian

Thank you. Good morning, and thank you for joining us on today's call. This morning, we issued a press release announcing our third quarter 2022 results and business updates, which is available on our website at interceptpharma.com.

Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our approved product and clinical development program, certain regulatory matters, and our strategy, prospects, financial guidance and future commercial and financial performance.

Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements, except as required by law.

These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

Some, but not necessarily all, of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.

Today's call will begin with prepared remarks from our President and CEO, Jerry Durso; our Chief Commercial Officer, Linda Richardson; President of Research and Development and Chief Medical Officer, Dr. Michelle Berrey; and Chief Financial Officer, Andrew Saik. We will then open the call to take questions.

Let me now turn the call over to our CEO, Jerry Durso.